CG Oncology, Inc., a late-stage biopharmaceutical company based in Irvine, United States, has announced its participation in two significant investor-focused healthcare conferences in May. The company, which specializes in developing and commercializing a potential bladder-sparing therapeutic for bladder cancer patients, will be represented by its chairman and chief executive officer, Arthur Kuan, and president and chief operating officer, Ambaw Bellete.
The first conference, the Bank of America Health Care Conference, will take place in Las Vegas on May 12. The second event, the RBC Capital Markets Global Healthcare Conference, is scheduled for May 20 in New York. At these conferences, CG Oncology will provide insights into its late-stage clinical work, focusing on the development of a bladder-sparing therapeutic aimed at improving the quality of life for bladder cancer patients. The company is particularly committed to advancing immunotherapy approaches in this area.
CG Oncology’s stock is traded on the Nasdaq stock exchange, and the company has a market capitalization of $5.91 billion USD. As of May 6, 2026, the close price of the stock was $69.18 USD, with a 52-week high of $73.56 USD on April 16, 2026, and a 52-week low of $23.32 USD on May 13, 2025.
The presentations at these conferences will be streamed live, and recordings will be available on the company’s Investor Relations website for a limited period following the events. CG Oncology’s communications and investor-relations teams are available for further inquiries, ensuring continued engagement with investors and stakeholders.
CG Oncology, Inc. operates within the medical sector of the United States and can be accessed through its website at www.cgoncology.com . The company’s commitment to innovation and patient care remains a cornerstone of its operations as it continues to advance its therapeutic developments.
